Portfolio News

 

   
December 15, 2011
CSA Medical Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in CSA Medical the leading developer of novel Spray Cryotherapy devices that freeze and destroy unwanted tissue inside the body as part of a £20.5m financing round. ...

Read more

Team - Paul LaViolette, David Milne
December 2011
TRANSENTERIX CLOSES $15M IN EQUITY FINANCING
Second tranche of Series B to accelerate development and commercialization of new flexible surgical tools SV Life Sciences notes that SV Life Sciences Fund IV invested in TransEnterix, maker of flexible medical devices that are changing how minimally invasive surgeries are performed today as part of a $15m Series B financing round. RESEARCH TRIANGLE PARK, N.C. – TransEnterix Inc. has closed $15 million in venture capital financing.

Read more

Team - Paul LaViolette, David Milne
December 2011
Catabasis Pharmaceuticals Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases as part of an $8m follow on series A financing round.  ...

Read more

Team - Michael Ross
November 2011
Rempex Pharmaceuticals Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in Rempex Pharmaceuticals, focused on developing internally discovered new treatments for resistant gram-negative infections as part of  $67.5m series B funding round. ...

Read more

Team - Michael Ross
November 2011
AcuFocus Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in AcuFocus, maker of an innovative corneal Inlay to improve the treatment of new vision loss (presbyopia) as part of a $65m financing round. ...

Read more

Team - James Garvey, David Guyer
October 2011
Concentric Medical Exit
SV Life Sciences notes that in October 2011 – Stryker (NYSE:SYK) entered into a definitive agreement to acquire Concentric Medical for £135m in an all-cash transaction.  ...

Read more

Team - James Garvey, Greg Madden
October 2011
WellNow Urgent Care Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in WellNow Urgent Care, an urgent care company focused on treating patients. Clinics offer you the convenience and expertise to treat everything that is non-life or limb threatening illness or injury as part of a $35m financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
October 2011
Coredia NC1 (Now Cibiem) Investment
SV Life Sciences notes that SV Life Science Fund V invested Coridea NC1, (which has since changed its name to Cibiem) - developer of CBM (Carotid Body Modulation) treatment of sympathetic nervous system-mediated diseases such as hypertension, heat failure, diabetes and renal failure as part of a $2m series S2 financing round. ...

Read more

Team - Paul LaViolette, David Milne
September 2011
TopiVert Investment
SV Life Sciences notes that SV Life Science Fund V invested in TopiVert, focused on developing topical medicines for inflammatory diseases of the eye and gut as part of a £8m financing round.   ...

Read more

Team - Kate Bingham, Graham Boulnois, Hamish Cameron, Michael Carter
August 17, 2011
Entellus Investment
SV Life Sciences notes that SV Life Sciences Fund IV invested in Entellus, maker of a novel balloon treatment for chronic Sinusitis as part of a $35m Series E financing round.  ...

Read more

Team - David Milne
August 2011
Autifony Therapeutics Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in Autifony Therapeutics which aims to find effective new drugs targeting voltage-gated ion channels which promise to treat hearing loss and tinnitus as part of £10.4m series A financing round. ...

Read more

Team - Kate Bingham, Graham Boulnois, Hamish Cameron, Michael Carter
July 6, 2011
Vantia Therapeutics Investment
SV Life Sciences notes that SV Life Sciences Fund IV invested in Vantia Therapeutics, an emergine pharmaceutifcal company developing novel, small molecule drugs as part of a £4m Series B financing round.  ...

Read more

Team - Kate Bingham
July 2011
CoreLab (Medifacts) - Investment
SV Life Sciences Fund III invested in CoreLab, provides ECG core lab services related to cardiac safety testing for global clinical trials as part of a $7m series C financing round. ...

Read more

Team - Eugene Hill
June 2011
Lux Biosciences - Investment
SV Life Sciences Fund III invested in Lux Biosciences, developing drugs for ophthalmic diseases. Their lead product is LX211, an oral drug for the treatment of uveitis as part of a $6m bridge loan financing round. ...

Read more

Team - David Guyer

⇧ Back to top